Bukwang Pharm Co Ltd
KRX:003000
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dupont De Nemours Inc
NYSE:DD
|
US |
|
Kirloskar Brothers Ltd
NSE:KIRLOSBROS
|
IN |
|
Kohinoor Foods Ltd
NSE:KOHINOOR
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (15.2), the stock would be worth ₩2 643.42 (64% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 41.9 | ₩7 290 |
0%
|
| 3-Year Average | 15.2 | ₩2 643.42 |
-64%
|
| 5-Year Average | 52.5 | ₩9 144.98 |
+25%
|
| Industry Average | 16.8 | ₩2 932.88 |
-60%
|
| Country Average | 8.5 | ₩1 487.8 |
-80%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Bukwang Pharm Co Ltd
KRX:003000
|
719.3B KRW | 41.9 | 73.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Bukwang Pharm Co Ltd
Glance View
Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.
